Determination of Target In-Vitro Drug Release Profile for Extended Release Formulation of Acyclovir through Pharmacokinetic Simulations

ISSN: 2211-3533 (Online)
ISSN: 2211-3525 (Print)


Volume 14, 2 Issues, 2016


Download PDF Flyer




Anti-Infective Agents

Formerly: Anti-Infective Agents in Medicinal Chemistry

This journal supports open access

Aims & ScopeAbstracted/Indexed in


Submit Abstracts Online Submit Manuscripts Online

View Full Editorial Board

Subscribe Purchase Articles Order Reprints


Determination of Target In-Vitro Drug Release Profile for Extended Release Formulation of Acyclovir through Pharmacokinetic Simulations



Anti-Infective Agents, 11(2): 204-211.

Author(s): R. Sankar and Subheet Kumar Jain.

Affiliation: Department of Pharmaceutical Sciences, Guru Nanak Dev University, Amritsar, Punjab, 143 005, India.

Abstract

Acyclovir, a widely used anti-viral drug, is the treatment of choice for initial episodes and management of recurrent episodes of genital herpes. Oral immediate release (IR) formulations of acyclovir have limitations of poor and variable bioavailability (15-30%), and dosing frequency up to five times a day. Such limitations lead to poor patient compliance and development of drug resistance. An oral extended release (ER) formulation of acyclovir can overcome these limitations. In the present study, a simple simulation technique for determination of the dose and in-vitro drug release profile required for an ER formulation of acyclovir to achieve steady state maximum and minimum plasma concentrations ( Cssmax and Cssmin ) similar to or better than those of an IR formulation, has been reported. First order drug release and absorption models were used. The dose and in-vitro drug release rate required for the ER formulation were found to be 725 mg and 0.259 h-1, respectively. Cssmax and Cssmin values of the ER formulation were 90% and 218%, respectively, compared to those of the IR formulation. The fluctuation index of the ER formulation ( FIER ) was 69% of that of the IR formulation ( FIIR ), indicating that the ER formulation can maintain more constant plasma concentrations than the IR formulation. Results of the simulation study indicated the feasibility of an ER formulation of acyclovir for twice daily administration. If the target in-vitro drug release and dose required for an ER formulation are known prior to initiation of formulation development, the number of experiments, cost and development time can be significantly reduced.

Keywords:

Acyclovir, conventional delivery limitations, extended release, oral delivery, simulation model, target in-vitro drug release.



Purchase Online Order Reprints Order Eprints Rights and Permissions




Article Details

Volume: 11
Issue Number: 2
First Page: 204
Last Page: 211
Page Count: 8
DOI: 10.2174/2211352511311020014
Price: $58
Advertisement

Related Journals




Webmaster Contact: urooj@benthamscience.org Copyright © 2016 Bentham Science